Abbott Cuts 2026 Growth View, Plans Nutrition Spin-Off — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Abbott cut its 2026 sales-growth view, placing a weaker top-line forecast alongside the planned separation of its nutrition business.
- Abbott plans to carve its nutrition operation into an independent company; companion WSJ and Bloomberg.com headlines describe the baby-formula unit as “embattled” or “troubled” and note that Abbott stock fell after earnings.
Why it matters: For Abbott shareholders, the post-earnings stock decline gives the 2026 sales-growth cut immediate weight, while the planned carve-out changes the corporate structure around the baby-formula nutrition operation. All four headlines agree on separation; the underemphasized combination is a portfolio reset alongside a lower growth view.
Ask SkimNews
